Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Hansoh Pharmaceutical’s partner, GlaxoSmithKline, has received FDA Breakthrough Therapy Designation for HS-20093, a novel lung cancer treatment, highlighting promising trial results. This endorsement will expedite the development of HS-20093, which is showing potential against small-cell lung cancer after initial chemotherapy failure. The full data will be unveiled at the upcoming World Conference on Lung Cancer in 2024.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.